EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution

Ninna Aggerholm-Pedersen, Peter Rasmussen, Helle Dybdahl, Philip Rossen, Ole Steen Nielsen, Akmal Safwat

ISRN Oncology · 2011

DOI: 10.5402/2011/523915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ISRN Oncology, 2011. Verfasst von Ninna Aggerholm-Pedersen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment with tyrosine kinase inhibitors (TKIs) has drastically improved overall survival (OS) of patients with advanced GIST. The aim of this study is to evaluate the results of treatment with different TKIs on advanced GIST and identify prognostic factors for OS. The medical records of all patients treated at the Department of Oncology, Aarhus University Hospital were retrospectively reviewed. Between 2001 and 2009, 80 patients with advanced GIST were treated with imatinib as first-line therapy. The median OS was 44 months (95% CI 31–56), and the 5-year OS was 40%. Since 2005, 32 patients were treated with sunitinib as 2nd-line therapy. The median time to progression was 9 months (95% CI: 3–13 months), and the 3-year OS was 30%. The data illustrate that data from large multicenter studies are reproducible in a single sarcoma centre. This retrospective study pointed to low serum sodium at the start of imatinib as a possible prognostic factor affecting OS.

Autor:innen und Institutionen

  • Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark.

Zitieren

APA

Aggerholm-Pedersen, N., Rasmussen, P., Dybdahl, H., Rossen, P., Nielsen, O. S., & Safwat, A. (2011). Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution. ISRN Oncology. https://doi.org/10.5402/2011/523915

Vancouver

Aggerholm-Pedersen N, Rasmussen P, Dybdahl H, Rossen P, Nielsen OS, Safwat A. Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution. ISRN Oncology. 2011. doi:10.5402/2011/523915

BibTeX
@article{AggerholmPedersen2011,
  author = {Aggerholm-Pedersen, Ninna and Rasmussen, Peter and Dybdahl, Helle and Rossen, Philip and Nielsen, Ole Steen and Safwat, Akmal},
  title = {Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution},
  journal = {ISRN Oncology},
  year = {2011},
  doi = {10.5402/2011/523915}
}
Kostenlos starten →